Enhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model

Matsushima,Masashi; Horinaga,Minoru; Fukuyama,Ryuichi; Yanaihara,Hitoshi; Kikuchi,Eiji; Kawachi,Makoto; Iida,Masahiro; Nakahira,Yoko; Oya,Mototsugu; Asakura,Hirotaka

doi:10.3892/ol.2010.217

Enhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model

Authors:
- Masashi Matsushima
- Minoru Horinaga
- Ryuichi Fukuyama
- Hitoshi Yanaihara
- Eiji Kikuchi
- Makoto Kawachi
- Masahiro Iida
- Yoko Nakahira
- Mototsugu Oya
- Hirotaka Asakura
View Affiliations

Affiliations: Department of Urology, Saitama Medical School, Saitama 350-0495, Japan, Department of Pathology, Konankosei Hospital, Aichi 483-8704, Japan, Department of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan
Published online on: November 23, 2010 https://doi.org/10.3892/ol.2010.217
Pages: 13-19

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Intravesical immunotherapy with bacillus Calmette-Guerin (BCG) is currently the most successful adjuvant agent for the treatment and/or prophylaxis of non-muscle-invasive bladder cancer (NMIBC). However, NMIBCs recur in 60-70% of cases and 30% of these recurrent tumors present with a higher grade and more invasive properties. Patients that do not respond to intravesical BCG therapy are considered to be a challenge for urologists. Thus, novel conservative possibilities should be explored. To test the efficacy of a novel therapeutic approach, we examined the antitumor effect of combination therapy by intravesical administration of mitomycin C (MMC) plus BCG, infusing the two drugs simultaneously, in an orthotopic bladder cancer model. Intravesical BCG and MMC administration showed a dose-dependent survival (n=8 per group). The combination of MMC and BCG provided a significant survival advantage compared to the BCG-alone (p=0.035) and MMC-alone groups (p=0.040) (n=8 per group). The group with combined MMC/BCG exhibited a survival period similar to that achieved with an amount eight times higher that of BCG (n=10 per group). Ki-67 labeling index of cancer cells, showing tumor proliferation, was significantly lower in the combined group compared to the BCG-alone (p<0.05), MMC-alone (p<0.01) and control groups (p<0.01). No difference was detected between the combined group and the BCG-alone group with regard to CD3, T-cell infiltration and CD68 macrophage activity. The combined MMC/BCG treatment decreased the tumor appearance rate, improved the survival period and reduced the cellular proliferation rate in tumors compared to the BCG-alone treatment. The results suggest that the combined intravesical MMC/BCG treatment induced an enhanced antitumor effect against bladder tumors. The combined MMC/BCG treatment also showed a survival period similar to that achieved using a dose eight times higher of BCG-alone.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin. 59:225–249. 2009.
2	Hsieh JT, Dinney CP and Chung LW: The potential role of gene therapy in the treatment of bladder cancer. Urol Clin North Am. 27:103–113. 2000. View Article : Google Scholar : PubMed/NCBI
3	Malmstrom PU, Sylvester RJ, Crawford DE, et al: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol. 56:247–256. 2009. View Article : Google Scholar
4	Bohle A and Brandau S: Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol. 170:964–969. 2003. View Article : Google Scholar : PubMed/NCBI
5	Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL and Catalona WJ: T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 150:1018–1023. 1993.PubMed/NCBI
6	Alexandroff AB, Jackson AM, O’Donnell MA and James K: BCG immunotherapy of bladder cancer: 20 years on. Lancet. 353:1689–1694. 1999.PubMed/NCBI
7	Witjes JA: Management of BCG failures in superficial bladder cancer: a review. Eur Urol. 49:790–797. 2006. View Article : Google Scholar : PubMed/NCBI
8	Rajala P, Kaasinen E, Rintala E, et al: Cytostatic effect of different strains of Bacillus Calmette-Guerin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. Urol Res. 20:215–217. 1992. View Article : Google Scholar
9	Kavoussi LR, Brown EJ, Ritchey JK and Ratliff TL: Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest. 85:62–67. 1990. View Article : Google Scholar
10	Horiguchi Y, Larchian WA, Kaplinsky R, Fair WR and Heston WD: Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther. 7:844–851. 2000. View Article : Google Scholar : PubMed/NCBI
11	Jacob DA, Bahra M, Langrehr JM, et al: Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J Gastroenterol Hepatol. 22:738–748. 2007.
12	De Boer EC, Rooijakkers SJ, Schamhart DH and Kurth KH: Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response. J Urol. 170:2004–2008. 2003.PubMed/NCBI
13	Tan BT, Limpens J, Koken M, Valster H and Scheper RJ: Local administration of various cytostatic drugs after subcutaneous immunization enhances delayed-type hypersensitivity reaction to sheep red blood cells in mice. Scand J Immunol. 23:605–609. 1986. View Article : Google Scholar
14	Zitvogel L, Apetoh L, Ghiringhelli F and Kroemer G: Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 8:59–73. 2008. View Article : Google Scholar : PubMed/NCBI
15	Nowak AK, Robinson BW and Lake RA: Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res. 62:2353–2358. 2002.PubMed/NCBI
16	Balemans LT, Vegt PD, Steerenberg PA, et al: Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guerin on the immune response in the guinea pig bladder. Urol Res. 22:239–245. 1994. View Article : Google Scholar : PubMed/NCBI
17	Witjes JA, Caris CT, Mungan NA, Debruyne FM and Witjes WP: Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol. 160:1668–1672. 1998. View Article : Google Scholar
18	Kaasinen E, Rintala E, Pere AK, et al: Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma. J Urol. 164:47–52. 2000. View Article : Google Scholar
19	Kaasinen E, Wijkstrom H, Malmstrom PU, et al: Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol. 43:637–645. 2003. View Article : Google Scholar : PubMed/NCBI
20	Di Stasi SM, Giannantoni A, Giurioli A, et al: Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 7:43–51. 2006.PubMed/NCBI
21	Ratliff TL: Role of animal models in understanding intravesical therapy with bacille Calmette-Guerin. Clin Infect Dis. 31(Suppl 3): 106–108. 2000. View Article : Google Scholar : PubMed/NCBI
22	Pan CW, Shen ZJ and Ding GQ: The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study. J Urol. 179:1307–1311. 2008. View Article : Google Scholar
23	Brandau S and Suttmann H: Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother. 61:299–305. 2007.PubMed/NCBI
24	DiPaola RS and Lattime EC: Bacillus Calmette-Guerin mechanism of action: the role of immunity, apoptosis, necrosis and autophagy. J Urol. 178:1840–1841. 2007. View Article : Google Scholar : PubMed/NCBI
25	Sasaki A, Kudoh S, Mori K, Takahashi N and Suzuki T: Are BCG effects against urinary bladder carcinoma cell line T24 correlated with apoptosis in vitro? Urol Int. 59:142–148. 1997. View Article : Google Scholar : PubMed/NCBI
26	Langford LA, Cooksley CS and DeMonte F: Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas. Hum Pathol. 27:350–354. 1996. View Article : Google Scholar : PubMed/NCBI
27	Asakura T, Takano Y, Iki M, et al: Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer. J Urol. 158:385–388. 1997. View Article : Google Scholar : PubMed/NCBI
28	Santos L, Amaro T, Costa C, et al: Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer. 105:267–272. 2003. View Article : Google Scholar : PubMed/NCBI